ReviewSeminars in oncology2010
Parathyroid cancer.
Review in Seminars in oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Giant parathyroid tumours in primary hyperparathyroidism: a systematic review.Langenbeck's archives of surgery · 2022Pooled it
- Case Report and Systematic Review: Sarcomatoid Parathyroid Carcinoma-A Rare, Highly Malignant Subtype.Frontiers in endocrinology · 2021Pooled it
- Current concepts in parathyroid carcinoma: a single Centre experience.BMC endocrine disorders · 2019Trial
- Revisiting parathyroid carcinoma through the lens of the 2022 WHO classification.Hormones (Athens, Greece) · 2026Article
- Association Between Biochemical Parameters, Parathyroid Gland Morphometry, and Dual-Phase MIBI SPECT/CT Findings in Primary Hyperparathyroidism.Journal of clinical medicine · 2026Article
- Current Knowledge on Atypical Parathyroid Tumors and Emerging Strategies for Risk Stratification.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Transcriptome sequencing reveals distinct atypical parathyroid tumor subtypes.Endocrine-related cancer · 2025Article
- Diagnostic and Therapeutic Challenges in Parathyroid Cancers: 15 Years' Experience in a Tertiary Center and an Endocrine Surgery Referral Hospital.Journal of clinical medicine · 2025Article
- Synchronous cancers including parathyroid carcinoma with urinary calculus as the initial sign.Journal of surgical case reports · 2025Article
- Article
- Giant Parathyroid Adenoma of the Posterior Mediastinum.Medicina (Kaunas, Lithuania) · 2024Article
- Parathyroid carcinoma: Imaging features of initial presentation and recurrence. A single center experience.The neuroradiology journal · 2024Article
- Late recurrence of a single gland primary hyperparathyroidism-Atypical parathyroid adenoma or misdiagnosed parathyroid carcinoma.Clinical case reports · 2024Article
- Diagnostic value of Tc-99m-MIBI SPECT/CT in parathyroid carcinoma with lung metastasis: a case report and literature review.Frontiers in oncology · 2024Article
- Case presentation of the smallest non-functional parathyroid carcinoma and review of the literature.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Review
- PARATHYROID CARCINOMA: ULTRASONOGRAPHIC AND CLINICAL EXPERIENCE.Acta clinica Croatica · 2023Article
- Effectiveness and safety of the radiofrequency ablation of single hyperfunctioning parathyroid lesions suggestive of adenomas in primary hyperparathyroidism.Journal of endocrinological investigation · 2023Article
- Multiple Metastases of Parathyroid and Papillary Thyroid Carcinoma in a Female Patient Treated with Long-Term Hemodialysis.Journal of personalized medicine · 2023Article
- [Casuistic cases of parathyroid carcinoma with a verified mutation in theProblemy endokrinologii · 2023Article
- Comparison of prognosis after partial and total surgical resection for parathyroid carcinoma: an inverse probability of treatment weighting analysis of the SEER database.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Parathyroid cancer is an uncommon malignancy and rare cause of primary hyperparathyroidism (HPT) with a high morbidity and patient death in advanced cases usually resulting from intractable hypercalcemia. Inactivation of the HRPT2/CDC73 gene, encoding the putative tumor-suppressor protein parafibromin and discovered in the context of the hyperparathyroidism-jaw tumor (HPT-JT) syndrome, is a common, somatic event in most parathyroid cancers. Approximately 25% of patients with apparently sporadic parathyroid cancer carry germline HRPT2/CDC73 mutation. Germline DNA analysis for HRPT2/CDC73 mutation is recommended in all patients with parathyroid cancer because of the potential benefit for first-degree relatives, who should nevertheless undergo serum calcium screening. The histopathologic diagnosis of parathyroid cancer is nonspecific unless vascular, lymphatic, capsular, or soft tissue invasion is seen, or metastases are clinically evident. Immunohistochemical analysis of parathyroid tumors for loss of parafibromin expression offers promise as a diagnostic tool. En bloc tumor resection offers the highest chance of cure in patients with suspected parathyroid carcinoma. No adjuvant chemotherapy regimen has yet proven effective, and the role of local adjuvant radiotherapy is being evaluated. Metastatic disease can be palliated with surgical debulking. Medical therapy with the calcimimetic cinacalcet and bisphosphonates can ameliorate hypercalcemia in patients with inoperable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.